• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过不同途径给兔和猴注射人γ干扰素后其体内循环干扰素的情况。

Circulating interferon in rabbits and monkeys after administration of human gamma interferon by different routes.

作者信息

Cantell K, Hirvonen S, Pyhälä L, De Reus A, Schellekens H

出版信息

J Gen Virol. 1983 Aug;64 (Pt 8):1823-6. doi: 10.1099/0022-1317-64-8-1823.

DOI:10.1099/0022-1317-64-8-1823
PMID:6409993
Abstract

Rabbits and rhesus monkeys were injected with 3 X 10(5) units of human gamma interferon (IFN) prepared in human leukocyte suspensions. Circulating IFN was detected up to 4 h after intravenous administration. Intramuscular injection maintained a relatively stable serum IFN level of about 50 units/ml for 7 to 9 h. The results in both species were similar. Little or no circulating IFN was detected after subcutaneous injection of 3 X 10(5) units, but 1.5 X 10(6) units maintained about 50 units per ml of serum for 30 h. Pharmacokinetically, human gamma IFN resembled human alpha interferons rather than human beta IFN.

摘要

给兔子和恒河猴注射了用人白细胞悬液制备的3×10⁵单位人γ干扰素(IFN)。静脉给药后长达4小时可检测到循环中的IFN。肌肉注射可使血清IFN水平在7至9小时内维持在约50单位/毫升的相对稳定状态。两个物种的结果相似。皮下注射3×10⁵单位后几乎检测不到或检测不到循环中的IFN,但1.5×10⁶单位可使血清中每毫升维持约50单位达30小时。从药代动力学角度来看,人γ干扰素类似于人α干扰素而非人β干扰素。

相似文献

1
Circulating interferon in rabbits and monkeys after administration of human gamma interferon by different routes.通过不同途径给兔和猴注射人γ干扰素后其体内循环干扰素的情况。
J Gen Virol. 1983 Aug;64 (Pt 8):1823-6. doi: 10.1099/0022-1317-64-8-1823.
2
Pharmacokinetics of human recombinant interferon-beta in monkeys and rabbits.人重组干扰素-β在猴和兔体内的药代动力学
Gan. 1984 Mar;75(3):292-300.
3
Pharmacokinetics of recombinant human interferon-gamma in the rhesus monkey after intravenous, intramuscular, and subcutaneous administration.重组人γ干扰素在恒河猴静脉内、肌肉内和皮下给药后的药代动力学
J Biol Response Mod. 1988 Apr;7(2):115-22.
4
Prevention of vaccinia lesions in Rhesus monkeys by human leucocyte and fibroblast interferon.人白细胞干扰素和成纤维细胞干扰素对恒河猴牛痘损伤的预防作用
J Gen Virol. 1980 May;48(1):25-30. doi: 10.1099/0022-1317-48-1-25.
5
Pharmacokinetics of human leukocyte interferon.人白细胞干扰素的药代动力学
J Infect Dis. 1976 Jun;133 Suppl:A6-12. doi: 10.1093/infdis/133.supplement_2.a6.
6
Circulating interferon in rabbits after simultaneous intramuscular administration of human alpha and gamma interferons.兔同时肌肉注射人α干扰素和γ干扰素后循环中的干扰素
J Interferon Res. 1984 Spring;4(2):291-3. doi: 10.1089/jir.1984.4.291.
7
Pharmacokinetic study of liposome-encapsulated human interferon-gamma after intravenous and intramuscular injection in mice.脂质体包裹的人γ-干扰素在小鼠静脉和肌肉注射后的药代动力学研究
J Interferon Res. 1990 Jun;10(3):337-41. doi: 10.1089/jir.1990.10.337.
8
[Pharmacokinetics of human interferons].[人类干扰素的药代动力学]
Gan To Kagaku Ryoho. 1984 Apr;11(4):935-42.
9
[Clinical trials of recombinant gamma-interferon. Circulating interferon and the 2,5-oligoadenylate synthetase activity after intramuscular and inhalation administrations].[重组γ干扰素的临床试验。肌肉注射和吸入给药后循环中的干扰素及2,5-寡腺苷酸合成酶活性]
Biull Eksp Biol Med. 1993 Jun;115(6):633-4.
10
Circulating interferon in rabbits after administration of human interferon by different routes.不同途径给予人干扰素后家兔体内循环干扰素的情况
J Gen Virol. 1973 Jul;20(1):97-104. doi: 10.1099/0022-1317-20-1-97.

引用本文的文献

1
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion.干扰素-γ 在肿瘤免疫监视或逃逸的十字路口。
Front Immunol. 2018 May 4;9:847. doi: 10.3389/fimmu.2018.00847. eCollection 2018.
2
Transfected Plasmodium knowlesi produces bioactive host gamma interferon: a new perspective for modulating immune responses to malaria parasites.转染的诺氏疟原虫产生具有生物活性的宿主γ干扰素:调节对疟原虫免疫反应的新视角。
Infect Immun. 2003 Aug;71(8):4375-81. doi: 10.1128/IAI.71.8.4375-4381.2003.
3
A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer.
Cancer Chemother Pharmacol. 1986;18(1):63-8. doi: 10.1007/BF00253067.